Chimeric Molecule Vaccine Platform for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current malaria vaccines face challenges due to antigen diversity, developmental stage specificity, and immune evasion mechanisms, leading to limited success in eliciting effective immune responses, particularly in overcoming T cell tolerance induced by malarial pathogens.
Innovation Solution
Development of chimeric molecules that provide T cell receptor interaction and costimulation, utilizing an immunoglobulin scaffold with linked costimulatory domains and pathogen-specific epitopes to activate and differentiate pathogen-specific T cells, and elicit antibodies against B cell epitopes, overcoming T cell tolerance and enhancing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional malaria vaccines (attenuated or killed whole pathogens, subunits) are used, then vaccine development is simplified, but immune responses are insufficient due to T cell tolerance induced by malarial pathogens
Solution Approach 1:
The patent combines multiple functional components into a single chimeric molecule: an immunoglobulin scaffold, costimulatory ligand (B7.1 or B7.2), and pathogen-specific T cell epitope. This merging allows the vaccine to simultaneously provide antigen recognition, costimulation, and T cell activation signals, overcoming T cell tolerance while maintaining a unified molecular structure that can be produced as a single recombinant protein.
Solution Approach 2:
The chimeric molecule functions as a composite biological material, integrating distinct functional domains from different sources (immunoglobulin framework, costimulatory molecules, and pathogen-derived epitopes) into a single molecule with synergistic immune-stimulating properties. This composite structure enables the vaccine to overcome the limitations of conventional single-antigen approaches.
2Object-affected harmful factors
If subunit vaccines are used, then vaccine safety is improved, but protection is limited due to antigen diversity and developmental stage specificity of malaria
Solution Approach 1:
The chimeric molecule is designed with universal applicability across different malaria stages and strains. The immunoglobulin scaffold provides a consistent platform for antigen presentation, while the costimulatory domains ensure broad T cell activation capability. The pathogen-specific epitope can be customized for different developmental stages (sporozoite, liver stage, blood stage) or geographic strains, making the platform universally applicable while maintaining stage- or strain-specific protection.
3Reliability
If chimeric molecules with costimulatory domains are developed, then T cell activation is enhanced, but manufacturing complexity increases
Solution Approach 1:
The chimeric molecule is constructed from modular segments that can be independently optimized and assembled. The immunoglobulin scaffold, costimulatory ligand domain, and T cell epitope are distinct functional modules that can be genetically engineered separately and then combined through standard recombinant DNA techniques. This segmentation simplifies the manufacturing process by allowing each module to be produced and validated independently before final assembly.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention relates to recombinant chimeric molecules that are capable of providing T cell receptor (TCR) interaction and costimulation for activation and differentiation of pathogen-specific T cells toward effector T helper 1 (Th I) or T helper 2 (Th2) cells. The chimera may capable of elicit antibodies against pathogen-specific B cell epitope(s). The present invention also relates method of using these chimeric molecules in whole or as a component of a vaccine.